DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prohance (Gadoteridol) - Disability - Suspected Cause - Side Effect Reports

 
 



Index of reports > Disability (17)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Prohance (Gadoteridol) disability. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Prohance side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-11

Patient: male, weighing 70.0 kg (154.0 pounds)

Reactions: Nephrogenic Systemic Fibrosis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prohance
    Indication: Renal Mass
    Start date: 2003-07-03
    End date: 2003-07-03

Omniscan
    Indication: Liver Disorder
    Start date: 2004-07-13
    End date: 2004-07-13

Omniscan
    Indication: Neck Pain
    Start date: 2004-07-13
    End date: 2004-07-13

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2004-07-13
    End date: 2004-07-13

Prohance
    Indication: Renal Scan
    Start date: 2003-07-03
    End date: 2003-07-03

Omniscan
    Indication: Osteomyelitis
    Start date: 2004-07-13
    End date: 2004-07-13

Contrast Media
    Indication: Decubitus Ulcer
    Start date: 2005-04-14
    End date: 2005-04-14

Magnevist

Prohance
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-04-14
    End date: 2005-04-14

Contrast Media
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-04-14
    End date: 2005-04-14

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-07-13
    End date: 2004-07-13

Multihance
    Indication: Diagnostic Procedure

Optimark

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2004-10-15
    End date: 2004-10-15

Other drugs received by patient: Plavix; Iron; Clonidine; Calcitriol; Proamatine; Epogen; Renvela; Cozaar; Calcium Carbonate; Metoprolol Tartrate; Sensipar; Rena-Vite; Phoslo; Hectorol; Renagel; Amlodipine; Fosrenol; Lisinopril; Foltx



Possible Prohance side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-06

Patient: male, weighing 70.0 kg (154.0 pounds)

Reactions: Pruritus, Hyperkeratosis, Pain, Skin Burning Sensation, Skin Hyperpigmentation, Erythema, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Fibrosis, Extremity Contracture, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, DRY Skin, Hypoaesthesia, Skin Induration, Deformity, Skin Tightness, Paraesthesia, Skin Plaque, Rash Macular, Gait Disturbance, Scar, Mobility Decreased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-04-14
    End date: 2005-04-14

Omniscan
    Dosage: 15 ml, unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2004-10-15
    End date: 2004-10-15

Prohance
    Dosage: 17 ml, once
    Indication: Nuclear Magnetic Resonance Imaging Abdominal
    Start date: 2003-07-03
    End date: 2003-07-03

Magnevist

Omniscan
    Dosage: 30 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2004-07-13
    End date: 2004-07-13

Prohance
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-04-14
    End date: 2005-04-14

Omniscan
    Indication: Nuclear Magnetic Resonance Imaging Abdominal

Optimark

Multihance

Other drugs received by patient: Calcitriol; Plavix; Fosrenol; Sensipar; Clonidine; Renvela; Rena-Vite; Calcium Carbonate; Metoprolol Tartrate; Renagel; Cozaar; Phoslo; Epogen; Hectorol; Iron; Amlodipine; Lisinopril; Proamatine; Foltx



Possible Prohance side effects in 78 year old male

Reported by a consumer/non-health professional from Japan on 2012-06-01

Patient: 78 year old male, weighing 56.0 kg (123.2 pounds)

Reactions: Joint Range of Motion Decreased, Skin Discolouration, Nephrogenic Systemic Fibrosis, Gait Disturbance, Skin Induration, Blood Creatinine Increased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Magnevist
    Dosage: 10 ml, once
    Indication: Metastases To Lymph Nodes
    Start date: 2008-07-29
    End date: 2008-07-29

Prohance
    Dosage: 26 ml, once
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-07-17
    End date: 2008-07-17

Other drugs received by patient: Selbex; Omeprazole; SG Granules; Loxonin; Digoxin; Neurotropin [organ Lysate, Standardized]; Metformin Hydrochloride; Olopatadine HCL; Omeprazole; Unasyn; Antebate; Warfarin Sodium; Lendormin; Adalat CC; Lasix; Strong NEO-Minophagen C; Flomox; Celestamine TAB; Atarax; Zefnart



Possible Prohance side effects in 78 year old male

Reported by a consumer/non-health professional from Japan on 2012-05-23

Patient: 78 year old male, weighing 56.0 kg (123.2 pounds)

Reactions: Joint Range of Motion Decreased, Skin Discolouration, Gait Disturbance, Skin Induration, Nephrogenic Systemic Fibrosis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Magnevist
    Dosage: 10 ml, once
    Indication: Diagnostic Procedure
    Start date: 2008-07-29
    End date: 2008-07-29

Prohance
    Dosage: 26 ml, once
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-07-17
    End date: 2008-07-17

Other drugs received by patient: Lasix; Strong NEO-Minophagen C; Lendormin; Omeprazole; Neurotropin [organ Lysate, Standardized]; Antebate; Flomox; Warfarin Sodium; Unasyn; Selbex; Olopatadine HCL; Atarax; Loxonin; Omeprazole; SG Granules; Digoxin; Celestamine TAB; Adalat CC; Zefnart; Metfformin Hydrochloride



Possible Prohance side effects in male

Reported by a physician from Japan on 2012-05-08

Patient: male, weighing 56.0 kg (123.2 pounds)

Reactions: Nephrogenic Systemic Fibrosis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-07-17
    End date: 2008-07-17

Meglumine Gadopentetate
    Indication: Diagnostic Procedure
    Start date: 2008-07-29
    End date: 2008-07-29

Meglumine Gadopentetate
    Indication: Metastases To Lymph Nodes
    Start date: 2008-07-29
    End date: 2008-07-29

Other drugs received by patient: Unasyn Oral / 00903601 /; Pyrazolones; Loxonin; Digoxin / 00017701 /; Omeprazole; Omeprazole; Lasix; Lendormin; Atarax; Strong NEO-Minophagen C; Antebate; Adalat CC; Flomox; Celestamine TAB; Lendormin; Atarax; Neurotropin; Warfarin Potassium; Selbex; Olopatadine HCL; Zefnart



Possible Prohance side effects in 43 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-30

Patient: 43 year old male, weighing 118.0 kg (259.6 pounds)

Reactions: Pain in Extremity, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Fibrosis, Depression, Mobility Decreased, Scar

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Omniscan
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-04-25
    End date: 2006-04-25

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: 20 ml, once
    Start date: 2006-05-21
    End date: 2006-05-21

Other drugs received by patient: Nephrocaps; Losartan Potassium; Aldactone; Insulin; Albumin (Human); Cardizem; Zemplar; Procardia XL; Aranesp; Catapres; Procrit; Phoslo



Possible Prohance side effects in male

Reported by a physician from Japan on 2012-04-24

Patient: male, weighing 56.0 kg (123.2 pounds)

Reactions: Nephrogenic Systemic Fibrosis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-07-17
    End date: 2008-07-17

Meglumine Gadopentetate
    Indication: Metastases To Lymph Nodes
    Start date: 2008-07-29
    End date: 2008-07-29

Meglumine Gadopentetate
    Indication: Diagnostic Procedure
    Start date: 2008-07-29
    End date: 2008-07-29

Other drugs received by patient: Flomox; Olopatadine HCL; Atarax; Omeprazole; Lasix; Neurotropin; Zefnart; Lendormin; Atarax; Antebate; Digoxin / 00017701 /; Warfarin Sodium; Celestamine TAB; Pyrazolones; Selbex; Lendormin; Omeprazole; Unasyn Oral / 00903601 /; Loxonin; Adalat CC; Strong NEO-Minophagen C



Possible Prohance side effects in male

Reported by a physician from Japan on 2012-04-19

Patient: male, weighing 56.0 kg (123.2 pounds)

Reactions: Nephrogenic Systemic Fibrosis

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Prohance
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2008-07-17
    End date: 2008-07-17

Meglumine Gadopentetate
    Indication: Diagnostic Procedure
    Start date: 2008-07-29
    End date: 2008-07-29

Meglumine Gadopentetate
    Indication: Metastases To Lymph Nodes
    Start date: 2008-07-29
    End date: 2008-07-29

Other drugs received by patient: Loxonin; Digoxin / 00017701 /; Adalat CC; Omeprazole; Zefnart; Lasix; Strong NEO-Minophagen C; Neurotropin; Pyrazolones; Warfarin Sodium; Celestamine TAB; Olopatadine HCL; Atarax; Omeprazole; Unasyn Oral / 00903601 /; Flomox; Lendormin; Antebate; Lendormin; Selbex; Atarax



Possible Prohance side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-05

Patient: female, weighing 78.7 kg (173.1 pounds)

Reactions: Pain, Abasia, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Fibrosis, Coordination Abnormal, Mobility Decreased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Magnevist
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-02-25
    End date: 2008-02-25

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-06-04
    End date: 2004-06-04

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-08-24
    End date: 2002-08-24

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-07-16
    End date: 2004-07-16

Optimark
    Indication: Imaging Procedure

Multihance
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-05-25
    End date: 2005-05-25

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-06-04
    End date: 2008-06-04

Omniscan
    Indication: Imaging Procedure

Prohance
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-05-17
    End date: 2004-05-17

Other drugs received by patient: Venofer; Aranesp; Clonidine; Metoprolol Succinate; Altace; Coumadin; Atenolol; Renagel; Enalapril Maleate; Epogen; Norvasc; Renvela



Possible Prohance side effects in 72 year old male

Reported by a consumer/non-health professional from United States on 2011-11-21

Patient: 72 year old male, weighing 97.5 kg (214.5 pounds)

Reactions: Restlessness, Urinary Incontinence, Dyskinesia, Toxicity To Various Agents, Tremor, NO Therapeutic Response, DRY Throat, Contrast Media Allergy, Hallucination, Asthenia, Nervousness, Muscle Spasms

Adverse event resulted in: life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Prohance



Possible Prohance side effects in 42 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-15

Patient: 42 year old male, weighing 81.0 kg (178.2 pounds)

Reactions: Skin Exfoliation, Joint Contracture, Pain, Post Inflammatory Pigmentation Change, Neuropathic Arthropathy, Stasis Dermatitis, Anhedonia, Joint Range of Motion Decreased, Skin Ulcer, Oedema, Rash Generalised, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, DRY Skin, Skin Induration, Skin Tightness, Rash Macular, Anxiety, Emotional Distress, Xerosis

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Magnevist
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 1999-08-18
    End date: 1999-08-18

Magnevist

Omniscan

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 2005-12-06
    End date: 2005-12-06

Optimark
    Dosage: 30 ml, once
    Start date: 2006-03-23
    End date: 2006-03-23

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2005-09-01
    End date: 2005-09-01

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Magnevist

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging Brain

Omniscan
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-05-16
    End date: 2006-05-16

Other drugs received by patient: Levothroid; Lotrel; Epogen; Lanoxin; Phoslo; Imuran; Ascorbic Acid W / Folic Acid / Iron / Vitamin B12; Protonix; Acyclovir; Morphine; Reglan; Pravachol; Neurontin; Quinine Sulfate; Imodium; Gastromark; Avinza; Niferex; Coumadin; Lantus; Novolog; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aciphex; Nephrocaps; Cyclosporine



Possible Prohance side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-10

Patient: female, weighing 78.7 kg (173.1 pounds)

Reactions: Pain, Abasia, Nephrogenic Systemic Fibrosis, Skin Induration, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Coordination Abnormal, Fibrosis, Mobility Decreased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2005-05-25
    End date: 2005-05-25

Optimark
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-08-24
    End date: 2002-08-24

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-02-25
    End date: 2008-02-25

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-07-16
    End date: 2004-07-16

Multihance
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2008-06-04
    End date: 2008-06-04

Magnevist
    Indication: Imaging Procedure

Prohance
    Indication: Imaging Procedure

Omniscan
    Indication: Imaging Procedure

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-05-17
    End date: 2004-05-17

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-06-04
    End date: 2004-06-04

Other drugs received by patient: Metoprolol; Renagel; Coumadin; Enalapril Maleate; Clonidine; Altace; Atenolol; Renvela; Epogen; Aranesp; Norvasc; Venofer



Possible Prohance side effects in 57 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-11-08

Patient: 57 year old male

Reactions: Renal Transplant, Nephrogenic Systemic Fibrosis, Immobile

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Prohance
    Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
    Start date: 2006-07-18
    End date: 2006-08-17

Prohance
    Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
    Start date: 2006-09-20
    End date: 2006-09-20

Prohance
    Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
    Start date: 2007-01-10
    End date: 2007-01-10

Prohance
    Dosage: 15 ml, single dose, 15 ml, single, 15 ml, single dose, 15 ml, single dose,
    Start date: 2007-05-01
    End date: 2007-05-01

Omniscan
    Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
    Indication: Central Nervous System Abscess
    Start date: 2006-05-13
    End date: 2006-05-13

Omniscan
    Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
    Indication: Central Nervous System Abscess
    Start date: 2006-08-23
    End date: 2006-08-23

Omniscan
    Dosage: 15 ml, single dose, intravenous;15 ml, single dose, intravenous; 15 ml, single dose, intravenous
    Indication: Central Nervous System Abscess
    Start date: 2006-08-31
    End date: 2006-08-31



Possible Prohance side effects in 73 year old male

Reported by a consumer/non-health professional from United States on 2011-11-08

Patient: 73 year old male

Reactions: Pain, Joint Contracture, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Anxiety, Emotional Distress, Anhedonia, Joint Range of Motion Decreased, Injury, Mobility Decreased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Omniscan
    Dosage: 20cc
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-07-15
    End date: 2002-07-15

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: 20cc injected
    Start date: 2002-07-15

Omniscan
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-05-14

Multihance
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Angioplasty
    Start date: 2004-06-21

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Indication: Imaging Procedure

Prohance
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-05-26

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-11-06

Magnevist
    Indication: Angiogram

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-07-10
    End date: 1999-07-10

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2002-07-18

Gadolinium IN Unspecified Drug
    Dosage: 30cc
    Start date: 2003-11-20

Other drugs received by patient: Flonase; Plavix; Metoprolol; Zocor; Coumadin; Singulair; Renagel; Sertraline Hydrochloride; Furosemide; Procrit; Allegra; Procrit; Iron [citric Acid,ferrous Sulfate]; Valsartan; Vitaplex; Actos; Glipizide; Ramipril



Possible Prohance side effects in 73 year old male

Reported by a lawyer from United States on 2011-11-08

Patient: 73 year old male

Reactions: Pain, Joint Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Emotional Distress, Anxiety, Anhedonia, Joint Range of Motion Decreased, Injury, Mobility Decreased

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Multihance
    Indication: Angiogram

Prohance
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2000-05-26

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: 20cc injected
    Start date: 2002-07-15

Gadolinium IN Unspecified Drug
    Dosage: 30cc
    Start date: 2003-11-20

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2002-07-18

Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Indication: Angiogram

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Angioplasty
    Start date: 2004-06-21

Magnevist
    Indication: Angiogram

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Angiogram

Omniscan
    Dosage: 20cc
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2002-07-15
    End date: 2002-07-15

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Nuclear Magnetic Resonance Imaging Brain
    Start date: 1999-07-10
    End date: 1999-07-10

Gadolinium IN Unspecified Drug
    Dosage: unk
    Indication: Angiogram
    Start date: 2001-05-14

Gadolinium IN Unspecified Drug
    Dosage: unk
    Start date: 2004-11-06

Gadolinium IN Unspecified Drug
    Indication: Imaging Procedure

Other drugs received by patient: Procrit; Coumadin; Plavix; Actos; Zocor; Renagel; Glipizide; Ramipril; Procrit; Singulair; Allegra; Sertraline Hydrochloride; Flonase; Vitaplex; Iron [citric Acid,ferrous Sulfate]; Furosemide; Valsartan; Metoprolol



Possible Prohance side effects in 52 year old female

Reported by a lawyer from United States on 2011-10-26

Patient: 52 year old female, weighing 149.0 kg (327.8 pounds)

Reactions: Skin Exfoliation, Pain, Abasia, Joint Contracture, Joint Stiffness, Joint Range of Motion Decreased, Skin Ulcer, Musculoskeletal Stiffness, Excoriation, Muscular Weakness, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Deformity, Pigmentation Disorder, Scar, Mobility Decreased

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Multihance
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2008-03-04
    End date: 2008-03-04

Magnevist
    Dosage: unk unk, once
    Indication: Angiogram
    Start date: 2003-09-13
    End date: 2003-09-13

Prohance
    Indication: Angiogram
    Start date: 2007-05-11
    End date: 2007-05-11

Prohance
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2007-11-09
    End date: 2007-11-09

Other drugs received by patient: Diovan; Iron; Renagel; Sensipar; Fosrenol; Epogen; Procrit; Amitriptyline HCL; Rocaltrol; Phoslo; Lantus; Humalog; Clonidine; Norvasc; Coreg; Altace; Aspirin



Possible Prohance side effects in 43 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-10

Patient: 43 year old male, weighing 118.0 kg (259.6 pounds)

Reactions: Pain in Extremity, General Physical Health Deterioration, Skin Induration, Nephrogenic Systemic Fibrosis, Deformity, Skin Tightness, Emotional Distress, Anxiety, Skin Discolouration, Depression, Fibrosis, Mobility Decreased, Scar

Adverse event resulted in: disablity

Drug(s) suspected as cause:
Magnevist
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: 20 ml, once
    Start date: 2006-05-21
    End date: 2006-05-21

Prohance
    Indication: Nuclear Magnetic Resonance Imaging

Omniscan
    Dosage: 20 ml, once
    Indication: Nuclear Magnetic Resonance Imaging
    Start date: 2006-04-25
    End date: 2006-04-25

Multihance
    Indication: Nuclear Magnetic Resonance Imaging

Optimark
    Indication: Nuclear Magnetic Resonance Imaging

Other drugs received by patient: Insulin [insulin]; Zemplar; Cardizem; Losartan Potassium; Albumin (Human); Aranesp; Phoslo; Catapres; Nephrocaps; Procardia XL; Procrit; Aldactone

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014